BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xenon Pharmaceuticals Inc. Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine


3/23/2011 7:25:52 AM

VANCOUVER, British Columbia, March 23, 2011 /PRNewswire/ -- Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

The Wightman Award is another major honour for Dr. Hayden, having previously been awarded the Order of Canada and Order of British Columbia, the Canadian Institutes of Health Research's Health Researcher of the Year Award, LifeSciences BC's Genome BC Award for Scientific Excellence and the Prix Galien Canada.

"I am thrilled to receive this award," said Dr. Hayden during the awards ceremony this morning in Toronto. "As a physician scientist, to whom chance has given unusual opportunities, I am deeply aware of the degree to which my own success today is built upon the work, cooperation and struggles of others."

"This is a wonderful moment for Michael and the Xenon team is extremely proud of Michael's profound achievements. His scientific and entrepreneurial talents and the commitment he has made to finding novel cures for difficult to treat diseases have made us a better company and Canada a better scientific community," said Dr. Simon Pimstone, a co-founder and President and Chief Executive Officer at Xenon Pharmaceuticals Inc. in Vancouver, Canada.

The Gairdner Awards are a highly respected international prize. Ten of the last 24 Nobel Prizes in medicine or physiology have been awarded to past Gairdner recipients. Prior to Dr. Hayden winning the Wightman Award, the last British Columbian to receive a Gairdner Award was the late UBC Chemistry Prof. Michael Smith, who won the 1986 Gairdner Foundation International Award and went on to win the 1993 Nobel Prize for Chemistry.

"I have known Michael and seen him in action for approximately twenty years and can think of no one in Canada more deserving," said Mr. Michael Tarnow, the Chairman of Xenon's Board of Directors and a past President and CEO of Merck Frosst Canada. "Michael's research is innovative, meaningful and far reaching and is touching lives and providing hope for patients and family members literally all over the world. Michael is a most deserving recipient."

An author of more than 600 publications, Dr. Hayden is the most cited author on Huntington's disease in the world. He is well known for having developed a predictive genetic test for Huntington's disease, which was the first ever predictive test for any genetic disorder. With Xenon he has also identified genes associated with rare disorders such as Tangier disease, juvenile hemochromatosis and congenital insensitivity to pain. These discoveries are leading to novel approaches for treating common diseases such as cardiovascular disease, anemia and pain.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism. For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Xenon Pharmaceuticals Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES